IPA’s Jain Predicts 3-4 Weeks To Meet Indian Shortages
Current IGBA Chair Also Insists On Global Collaboration For Vaccine
Speaking exclusively to Generics Bulletin, Indian Pharmaceutical Alliance secretary general Sudarshan Jain says that India’s needs for COVID drugs like favipiravir, remdesivir and tocilizumab will be met “in the near future.” Current IGBA chair Jain also talks about global collaboration by governments and donors for equal vaccine distribution through the Access to COVID-19 Tools Accelerator.
You may also be interested in...
To tackle the increase in demand for remdesivir in India amidst the second wave of COVID-19, Gilead Sciences is helping local licensees to scale up production of the product, including by providing API supplies. The company is also donating at least 450,000 vials of the Veklury brand “to help address the immediate needs of Indian patients.”
India has approved a $46m project by giving the green light to 16 drug production applications under the Production Linked Incentive scheme. The government has ordered the setting up and commercial production of the 16 projects to commence immediately.
The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.